Endocrine Abstracts

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary tumour syndrome inherited in an autosomal dominant manner and characterized by a predisposition to a multitude of endocrine neoplasms primarily of parathyroid, enteropancreatic, and anterior pituitary origin, as well as nonendocrine neoplasms. However, thyroid cancer is not part of this syndrome. Case details: We report the case of a 36-year-old man diagnosed with primary hyper...

Introduction: The use of radioiodine is a common treatment for differentiated thyroid cancer. However, special care should be exercised in treating patients who are on hemodialysis, due to the renal elimination of the radionuclide, which implies several technical difficulties and safety concerns. We have previously described the procedure and the short-term outcome and safety in three patients (Jimenez et al, Thyroid 2001; 11(11):1031–1034). Our results showed that the ra...

Introduction: In transsexualism, cross-sex hormone treatment (CHT) both improves and impairs several surrogate cardiovascular risk markers in female to male (FtoM). Few randomized trials on CHT with long follow-up and control group are available, and present evidence is inconsistent. We here assess changes in metabolic and cardiovascular risk after 12 months CHT compared with biological sex in FtoM GID.Methods: Prospective observational study, including ...

There is a specific unit specialised in treating differentiated thyroid cancer (DTC) at the Endocrinology Department from a hospital the southwest of Spain that attends patients from two different provinces. Owing to environmental pollution, one of them has higher incidence of cancer.To evaluate the changes in the clinical presentation of DTC over time and analyse possible differences between patients from the two provinces, we designed a descriptive ret...

Objectives: Most transgender persons (0.3-0.5% of total population) are under gender-affirming hormone therapy (GAHT). Several studies have reported an increased morbimortality due to cardiovascular events (CVE), infectious disease and suicide. However, these studies were made on small populations and short follow up. We evaluated the changes on anthropometric variables, risk factors for cardiovascular diseases (CVD) and CVE at 5 and 10 years of follow up in a transgender popu...

Introduction: First treatment in Graves’ disease consists in the administration of antithyroid drugs. The most common side effect is a rash, which affects about 5% patients and clears up if the drug is stopped. The other drug may then be used. The intolerance to both drugs is very rare, but in this situation early radioactive iodine or surgery may be the answer.Case report: Woman of 61 years old who developed primary hyperthiroidism, with levels of ...

Introduction: The immunohistochemical characterization of Pit-1, Tpit and SF-1 transcription factors allows the identification of the three adenohypophyseal cell lines and has been incorporated into the latest WHO classification of pituitary adenomas (PA). The aim of the present study was to quantify the protein expression of pituitary-specific transcription factors (TF) by immunohistochemistry (IHC) and to correlate these results with the identification based on hormonal prot...

BackgroundTranssphenoidal surgery is in general the preferred first-line treatment for patients with macroadenomas except for prolactinomas, which is mainly indicated when the treatment with dopamine agonists (DA) fails. However, in those patients resistant to DA (i.e. volume reduction ObjectiveTo identify predictors of DA resistance in order...

Introduction: Primary aldosteronism (PA) is the most common cause of secondary hypertension. Guidelines recommend a confirmatory test in the majority of suspected cases: oral sodium loading, saline infusion test (SIT), captopril challenge test (CCT), or fludrocortisone suppression test. The SIT and CCT are most commonly used in clinical practice to study autonomous aldosterone secretion.Objectives and Methods: We compared the CCT’s diagnosis perform...

Objectives: Semaglutide was approved for the treatment of T2DM patients with a body mass index (BMI) > 30kg/m2 by the Spanish National Health Service in May 2019. We evaluate clinical outcomes of patients on previous treatment with any another GLP1–RA that switch to Semaglutide.Material and Methods: Retrospective analysis. Sixty–five T2DM patients were included. Demographic data, anthropometric, systolic blood pressure (SBP), d...